| Hazard Information | Back Directory | [Uses]
Siltuximab it is used for cancer treatment using anti-ICOS antibody if patient has low peripheral T cell receptor clonality. | [Clinical Use]
Chimeric (human-murine) immunoglobulin G1κ
(IgG1κ) monoclonal antibody:
Treatment of multicentric Castleman’s disease
(MCD) | [Drug interactions]
Potentially hazardous interactions with other drugs
Live vaccines: risk of generalised infections - avoid.
Ciclosporin and tacrolimus: monitor levels on
initiation and discontinuation of siltuximab as it may
reduce the activity of CYP450. | [Metabolism]
As siltuximab is a monoclonal antibody, the expected
consequence of metabolism is proteolytic degradation to
small peptides and individual amino acids, and receptormediated clearance. |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
|